Stubbs et al - TMAO and CV Outcomes in EVOLVE_CJASN.pdf (541.32 kB)

Stubbs et al - TMAO and CV Outcomes in EVOLVE_CJASN.pdf

Download (541.32 kB)
journal contribution
posted on 14.03.2019 by Jason Stubbs, Margaret Stedman, Sai Liu, Jin Long, Yoko Franchetti, Raymond West III, Alex Prokopienko, Jonathan Mahnken, Glenn Chertow, Tom Nolin
The data demonstrates that baseline levels of TMAO, a circulating compound derived from byproducts of intestinal bacteria, do not predict cardiovascular endpoints in patients with end-stage kidney disease.

History

Grant ID

15GRNT25700231

Licence

Exports